Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.40 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3086532 | 0.80 | SMN1; SMN2 (0.56) | SMN1; SMN2MAPTPOLBEGFRALDH1A1 | |
| SCHEMBL29977958 | 0.75 | SMN1; SMN2 (0.59) | SMN1; SMN2MAPTPOLBEGFRALDH1A1 | |
| SCHEMBL1256644 | 0.75 | SMN1; SMN2 (0.59) | SMN1; SMN2MAPTPOLBEGFRALDH1A1 | |
| SCHEMBL23904091 | 0.73 | SMN1; SMN2 (0.53) | SMN1; SMN2MAPTPOLBEGFRALDH1A1 | |
| SCHEMBL23845573 | 0.73 | MAPT (0.60) | SMN1; SMN2MAPTPOLBALDH1A1MEN1 | |
| SCHEMBL23833598 | 0.72 | SMN1; SMN2 (0.60) | SMN1; SMN2MAPTPOLBEGFRALDH1A1 | |
| SCHEMBL23845470 | 0.69 | ALDH1A1 (0.54) | SMN1; SMN2MAPTPOLBALDH1A1MEN1 | |
| SCHEMBL23845463 | 0.69 | SMN1; SMN2 (0.53) | SMN1; SMN2MAPTPOLBEGFRALDH1A1 | |
| SCHEMBL17509 | 0.68 | SMN1; SMN2 (0.56) | SMN1; SMN2MAPTPOLBEGFRALDH1A1 | |
| SCHEMBL29483829 | 0.68 | SMN1; SMN2 (0.56) | SMN1; SMN2MAPTPOLBEGFRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365529-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. | 2023-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365529-A1 | PARP7 INHIBITORS | PARP1, PARP11, PARP2 | SMN1; SMN2 2629/4885MAPT 2243/4885POLB 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.